| Literature DB >> 31488490 |
Imtiaz Jehan1, H Asita de Silva2, Aliya Naheed3, Liang Feng4, Hamida Farazdaq5, Samina Hirani1, Anuradhani Kasturiratne6, Channa D Ranasinha2, Md Tauhidul Islam3, Ali Tanweer Siddiquee3, Tazeen H Jafar7.
Abstract
OBJECTIVE: To determinate the prevalence and correlates of cardiometabolic multimorbidity (CMM), and their cross-country variation among individuals with hypertension residing in rural communities in South Asia.Entities:
Keywords: South Asia; cardiometabolic multimorbidity; hypertension; obesity
Mesh:
Year: 2019 PMID: 31488490 PMCID: PMC6731877 DOI: 10.1136/bmjopen-2019-030584
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline characteristics by status of cardio-metabolic multimorbidity* (n=2288)
| Characteristics | All | Cardiometabolic multimorbidity | P value | |
| Yes (n=581) | No (n=1707) | |||
| Age (y), n (%) | <0.001 | |||
| 40–49 | 566 (24.7) | 92 (15.8) | 474 (27.8) | . |
| 50–59 | 633 (27.7) | 138 (23.8) | 495 (29.0) | . |
| 60–69 | 660 (28.8) | 203 (34.9) | 457 (26.8) | . |
| 70 and over | 429 (18.8) | 148 (25.5) | 281 (16.5) | . |
| Male, n (%) | 817 (35.7) | 217 (37.3) | 600 (35.1) | 0.34 |
| Formal education (vs informal), n (%) | 1396 (61.0) | 431 (74.2) | 965 (56.5) | <0.001 |
| Married (vs others), n (%) | 1679 (73.4) | 399 (68.7) | 1280 (75.0) | 0.003 |
| International Wealth Index score, n (%) | <0.001 | |||
| 0–43 | 539 (23.6) | 83 (14.3) | 456 (26.8) | . |
| 43–60 | 596 (26.1) | 158 (27.2) | 438 (25.7) | . |
| 60–73 | 555 (24.3) | 159 (27.4) | 396 (23.3) | . |
| 73 and above | 591 (25.9) | 180 (31.0) | 411 (24.2) | . |
| Current smoker (vs current non-smoker), n (%) | 236 (10.3) | 55 (9.5) | 181 (10.6) | 0.44 |
| Physical activity level (MET-min/week), n (%) | <0.001 | |||
| Inactive | 603 (26.7) | 157 (27.5) | 446 (26.4) | . |
| Minimally active | 512 (22.7) | 164 (28.7) | 348 (20.6) | . |
| Highly active | 1144 (50.6) | 250 (43.8) | 894 (53.0) | . |
| BMI (kg/m2), n (%) | 0.001 | |||
| <18.5 | 204 (8.9) | 29 (5.0) | 175 (10.3) | . |
| 18.5–23.0 | 656 (28.7) | 166 (28.7) | 490 (28.8) | . |
| 23.0–27.5 | 849 (37.2) | 231 (39.9) | 618 (36.3) | . |
| 27.5 and above | 573 (25.1) | 153 (26.4) | 420 (24.7) | . |
| Waist circumference† (cm), n (%) | <0.001 | |||
| 0–Q1 | 543 (23.8) | 93 (16.0) | 450 (26.4) | . |
| Q1–Q2 | 570 (24.9) | 139 (24.0) | 431 (25.3) | . |
| Q2–Q3 | 554 (24.2) | 174 (30.0) | 380 (22.3) | . |
| Q3 and above | 619 (27.1) | 174 (30.0) | 445 (26.1) | . |
| Family history of CVD, n (%) | 593 (26.5) | 177 (31.3) | 416 (24.9) | 0.003 |
| Country, n (%) | <0.001 | |||
| Bangladesh | 819 (35.8) | 224 (38.6) | 595 (34.9) | . |
| Pakistan | 679 (29.7) | 70 (12.0) | 609 (35.7) | . |
| Sri Lanka | 790 (34.5) | 287 (49.4) | 503 (29.5) | . |
| HDL (mg/dL), mean (SD) | 45.3 (12.8) | 45.3 (12.8) | 45.3 (12.8) | 0.98 |
| Triglyceride (mg/dL), median (IQR) | 128.7 (94.0,183.0) | 132.8 (99.3,192.0) | 127.0 (91.8,179.1) | <0.001 |
| Total cholesterol (mg/dL), mean (SD) | 194.6 (48.5) | 197.4 (52.0) | 193.6 (47.2) | 0.12 |
| LDL (mg/dL), mean (SD) | 124.4 (40.6) | 124.0 (43.8) | 124.5 (39.4) | 0.82 |
| Statin use, n (%) | 315 (13.8) | 156 (26.9) | 159 (9.3) | <0.001 |
*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
†Cardiometabolic multimorbidity was defined as as the presence of two or more chronic conditions of diabetes, heart disease, CKD and stroke.
BMI, body mass index;CKD, chronic kidney disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task.
Prevalence of cardiometabolic conditions stratified by quartiles of waist circumference among all individuals with hypertension (n=2286)
| Cardiometabolic conditions**, n (% (95% CI)) | Total | 0–Q1 | Q1–Q2 | Q2–Q3 | Q3 and over | P value for trend |
| Cardiometabolic multimorbidity* | 580 (25.4 (23.6 to 27.2)) | 93 (17.1 (14.1 to 20.6)) | 139 (24.4 (20.9 to 28.1)) | 174 (31.4 (27.6 to 35.5)) | 174 (28.1 (24.6 to 31.8)) | <0.001 |
| Single cardiometabolic condition | 807 (35.3 (33.3 to 37.3)) | 198 (36.5 (32.4 to 40.7)) | 199 (34.9 (31.0 to 39.0)) | 196 (35.4 (31.4 to 39.5)) | 214 (34.6 (30.8 to 38.5)) | 0.56 |
| Three or more cardiometabolic conditions | 129 (5.6 (4.7 to 6.7)) | 15 (2.8 (1.6 to 4.5)) | 27 (4.7 (3.1 to 6.8)) | 44 (7.9 (5.8 to 10.5)) | 43 (6.9 (5.1 to 9.2)) | <0.001 |
| Chronic kidney disease (CKD)† | 875 (38.3 (36.3 to 40.3)) | 208 (38.3 (34.2 to 42.5)) | 213 (37.4 (33.4 to 41.5)) | 218 (39.4 (35.3 to 43.6)) | 236 (38.1 (34.3 to 42.1)) | 0.88 |
| Diabetes‡ | 622 (27.2 (25.4 to 29.1)) | 61 (11.2 (8.7 to 14.2)) | 140 (24.6 (21.1 to 28.3)) | 190 (34.3 (30.3 to 38.4)) | 231 (37.3 (33.5 to 41.3)) | <0.001 |
| Heart disease§ | 317 (13.9 (12.5 to 15.4)) | 45 (8.3 (6.1 to 10.9)) | 84 (14.7 (11.9 to 17.9)) | 105 (19.0 (15.8 to 22.5)) | 83 (13.4 (10.8 to 16.3)) | 0.005 |
| Stroke¶ | 293 (12.8 (11.5 to 14.3)) | 85 (15.7 (12.7 to 19.0)) | 70 (12.3 (9.7 to 15.3)) | 79 (14.3 (11.5 to 17.5)) | 59 (9.5 (7.3 to 12.1)) | 0.008 |
*Cardiometabolic multimorbidity was defined as the presence of two or more chronic conditions of diabetes, heart disease, CKD and stroke.
†CKD was defined as the presence of estimated glomerular filtration rate ≤60 mL/min/1.73 m2 or urine albumin and creatinine ratio ≥30 mg/g.
‡Diabetes was defined as a fasting plasma glucose ≥126 mg/dL or self-reported use of antidiabetic medication.
§Heart disease was acertained based on self-reported physician diagnosis.
¶Stroke was determined if an invidual ever had unconciousness or had both abnormal speech and paralysed face.
** Cardiometabolic conditions included diabetes, heart disease, CKD and stroke.
Multivariate predictors of cardiometabolic multimorbidity among hypertensive individuals in rural Bangladesh, Pakistan and Sri Lanka
| Variables | Model 1 (n=2288) | Model 2 (n=2275) | Model 3 (n=2191) | |||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Country | <0.001 | <0.001 | <0.001 | |||
| Pakistan | 1.00 | 1.00 | 1.00 | |||
| Bangladesh | 3.28 (2.41 to 4.47) | <0.001 | 3.22 (2.41 to 4.29) | <0.001 | 3.42 (2.52 to 4.65) | <0.001 |
| Sri Lanka | 4.98 (3.76 to 6.58) | <0.001 | 3.40 (2.50 to 4.63) | <0.001 | 3.73 (2.48 to 5.61) | <0.001 |
| Age (year) | <0.001 | <0.001 | ||||
| 40–49 | 1.00 | 1.00 | ||||
| 50–59 | 1.35 (0.99 to 1.86) | 0.060 | 1.29 (0.94 to 1.77) | 0.12 | ||
| 60–69 | 2.08 (1.51 to 2.86) | <0.001 | 1.82 (1.31 to 2.53) | <0.001 | ||
| 70 and over | 2.59 (1.81 to 3.70) | <0.001 | 2.33 (1.59 to 3.40) | <0.001 | ||
| Gender | 0.32 | 0.58 | ||||
| Male | 1.00 | 1.00 | ||||
| Female | 0.86 (0.63 to 1.16) | 0.32 | 0.92 (0.67 to 1.25) | 0.58 | ||
| Education | 0.046 | 0.17 | ||||
| Informal | 1.00 | 1.00 | ||||
| Formal | 1.29 (1.00 to 1.64) | 0.046 | 1.20 (0.93 to 1.56) | 0.17 | ||
| Marital status | 0.15 | 0.18 | ||||
| Single or widowed or divorced | 1.00 | 1.00 | ||||
| Married | 0.82 (0.63 to 1.08) | 0.15 | 0.82 (0.62 to 1.10) | 0.18 | ||
| International Wealth Index score | 0.025 | 0.014 | ||||
| 0–43 | 1.00 | 1.00 | ||||
| 43–60 | 1.60 (1.11 to 2.31) | 0.012 | 1.63 (1.09 to 2.44) | 0.018 | ||
| 60–73 | 1.64 (1.14 to 2.36) | 0.008 | 1.69 (1.12 to 2.55) | 0.013 | ||
| 73 and above | 1.38 (0.93 to 2.04) | 0.11 | 1.29 (0.84 to 1.97) | 0.25 | ||
| BMI (kg/m2) | <0.001 | 0.24 | ||||
| <18.5 | 1.00 | 1.00 | ||||
| 18.5–23.0 | 1.85 (1.30 to 2.65) | <0.001 | 1.17 (0.78 to 1.76) | 0.45 | ||
| 23.0–27.5 | 2.13 (1.45 to 3.14) | <0.001 | 0.90 (0.57 to 1.42) | 0.65 | ||
| 27.5 and above | 2.44 (1.62 to 3.66) | <0.001 | 0.89 (0.56 to 1.41) | 0.61 | ||
| Smoking | 0.87 | |||||
| Non-current smoker | 1.00 | |||||
| Current smoker | 1.04 (0.66 to 1.64) | 0.87 | ||||
| Physical activity level (MET-min/week) | 0.010 | |||||
| Inactive | 1.00 | |||||
| Minimally active | 0.97 (0.71 to 1.30) | 0.82 | ||||
| Highly active | 0.75 (0.57 to 0.97) | 0.029 | ||||
| Waist circumference* (cm) | <0.001 | |||||
| 0–Q1 | 1.00 | |||||
| Q1–Q2 | 1.43 (1.03 to 1.99) | 0.033 | ||||
| Q2–Q3 | 2.15 (1.42 to 3.25) | <0.001 | ||||
| Q3 and above | 2.14 (1.50 to 3.06) | <0.001 | ||||
| Family history of CVD | 0.55 | |||||
| No | 1.00 | |||||
| Yes | 1.08 (0.84 to 1.37) | 0.55 | ||||
| Statin use | <0.001 | |||||
| Non-user | 1.00 | |||||
| User | 2.43 (1.84 to 3.22) | <0.001 | ||||
| HDL (mg/dL, per 5 mg/dL increase) | 0.96 (0.89 to 1.02) | 0.17 | ||||
| Triglyceride(mg/dL, per 5 mg/dL increase | 1.01 (1.01 to 1.02) | <0.001 | ||||
| LDL (mg/dL, per 5 mg/dL increase) | 1.00 (0.98 to 1.01) | 0.57 | ||||
*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task.
Figure 1Multiple-adjusted log (ORs) and 95% CIs of cardiometabolic multimorbidity with International Wealth Index Score. A was based on model 3 in table 3, while B was derived based on the model adjusted for only age and gender.